University of GenevaSwiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026.
ADVERTISEMENT
Swiss cancer specialist FoRx Therapeutics AG has secured US$50m Series A to fund Phase I development of FORX-428, supporting IND, trial execution and clinical data readout by mid-2026.